228 related articles for article (PubMed ID: 31036465)
1. Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men.
Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
Clin Genitourin Cancer; 2019 Jun; 17(3):e387-e393. PubMed ID: 31036465
[TBL] [Abstract][Full Text] [Related]
2. The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.
Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
Cancer Chemother Pharmacol; 2019 May; 83(5):933-938. PubMed ID: 30868236
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
[TBL] [Abstract][Full Text] [Related]
4. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):191-6. PubMed ID: 26857022
[TBL] [Abstract][Full Text] [Related]
5. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer.
Shiota M; Fujimoto N; Takeuchi A; Kashiwagi E; Dejima T; Inokuchi J; Tatsugami K; Yokomizo A; Kajioka S; Uchiumi T; Eto M
J Urol; 2018 Mar; 199(3):734-740. PubMed ID: 28941922
[TBL] [Abstract][Full Text] [Related]
6. Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.
Shiota M; Narita S; Akamatsu S; Fujimoto N; Sumiyoshi T; Fujiwara M; Uchiumi T; Habuchi T; Ogawa O; Eto M
JAMA Netw Open; 2019 Feb; 2(2):e190115. PubMed ID: 30794306
[TBL] [Abstract][Full Text] [Related]
7. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer.
Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
Andrologia; 2018 Dec; 50(10):e13119. PubMed ID: 30084497
[TBL] [Abstract][Full Text] [Related]
11. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
12. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
13. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
14. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
15. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
Sharifi N; Hamada A; Sissung T; Danesi R; Venzon D; Baum C; Gulley JL; Price DK; Dahut WL; Figg WD
BJU Int; 2008 Aug; 102(5):617-21. PubMed ID: 18537956
[TBL] [Abstract][Full Text] [Related]
16. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
[TBL] [Abstract][Full Text] [Related]
17. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
18. Impact of Androgen Deprivation Therapy on Overall Mortality in Prostate Brachytherapy Patients With Low Pretreatment Testosterone Levels.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Adamovich E
Am J Clin Oncol; 2018 Jul; 41(7):667-673. PubMed ID: 27740974
[TBL] [Abstract][Full Text] [Related]
19. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
20. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD; AbuAli G; Reichard CA; Reddy CA; Magi-Galluzzi C; Chang KH; Carlson R; Rangel L; Reagan K; Davis BJ; Karnes RJ; Kohli M; Tindall D; Klein EA; Sharifi N
Lancet Oncol; 2016 Oct; 17(10):1435-1444. PubMed ID: 27575027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
